BIMZELX[ ®] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

18 OCTOBER 2023 – 07:00 (CEST) – Regulated Information – Inside Information – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis in adults who…#ucb #fda #il17a #vivid #todaysfda #bimzelx #emmanuelcaeymaex #immunologysolutions #il17f #marklebwohl
Source: Reuters: Health - Category: Consumer Health News Source Type: news